BRPI0918653A2 - combinação de inibidor de ns3 protese de hcv com interferon e ribavirina. - Google Patents
combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.Info
- Publication number
- BRPI0918653A2 BRPI0918653A2 BRPI0918653A BRPI0918653A BRPI0918653A2 BR PI0918653 A2 BRPI0918653 A2 BR PI0918653A2 BR PI0918653 A BRPI0918653 A BR PI0918653A BR PI0918653 A BRPI0918653 A BR PI0918653A BR PI0918653 A2 BRPI0918653 A2 BR PI0918653A2
- Authority
- BR
- Brazil
- Prior art keywords
- ribavirin
- hcv
- prosthesis
- interferon
- inhibitor combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9775308P | 2008-09-17 | 2008-09-17 | |
US10903308P | 2008-10-28 | 2008-10-28 | |
US17193509P | 2009-04-23 | 2009-04-23 | |
PCT/US2009/056771 WO2010033443A1 (en) | 2008-09-17 | 2009-09-14 | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0918653A2 true BRPI0918653A2 (pt) | 2015-12-01 |
Family
ID=41571875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0918653A BRPI0918653A2 (pt) | 2008-09-17 | 2009-09-14 | combinação de inibidor de ns3 protese de hcv com interferon e ribavirina. |
Country Status (25)
Country | Link |
---|---|
US (1) | US8399484B2 (pt) |
EP (1) | EP2337583A1 (pt) |
JP (1) | JP5539363B2 (pt) |
KR (1) | KR20110054003A (pt) |
CN (1) | CN102159245B (pt) |
AR (1) | AR073516A1 (pt) |
AU (1) | AU2009293493B2 (pt) |
BR (1) | BRPI0918653A2 (pt) |
CA (1) | CA2737376A1 (pt) |
CL (1) | CL2011000571A1 (pt) |
CO (1) | CO6351753A2 (pt) |
EA (1) | EA019965B1 (pt) |
EC (1) | ECSP11010877A (pt) |
HK (1) | HK1156865A1 (pt) |
IL (1) | IL210152A0 (pt) |
MA (1) | MA32634B1 (pt) |
MX (1) | MX2011002602A (pt) |
MY (1) | MY152824A (pt) |
NZ (1) | NZ591030A (pt) |
PE (1) | PE20110343A1 (pt) |
TW (1) | TWI454263B (pt) |
UA (1) | UA103496C2 (pt) |
UY (1) | UY32124A (pt) |
WO (1) | WO2010033443A1 (pt) |
ZA (1) | ZA201009151B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
MX2011002602A (es) | 2008-09-17 | 2011-04-07 | Boehringer Ingelheim Int | Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina. |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
EP2483290A4 (en) * | 2009-09-28 | 2013-05-01 | Intermune Inc | CYCLIC PEPTIC INHIBITORS FOR REPLICATION OF HEPATITIS C VIRUS |
NZ598465A (en) * | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
US20120135949A1 (en) * | 2010-09-30 | 2012-05-31 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection |
EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
AU2011352145A1 (en) | 2010-12-30 | 2013-07-18 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
WO2012096852A2 (en) * | 2011-01-10 | 2012-07-19 | Proteus Biomedical, Inc. | System, method, and article to prompt behavior change |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
TW201600087A (zh) | 2011-10-21 | 2016-01-01 | 艾伯維有限公司 | 治療c型肝炎病毒(hcv)的方法 |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
DK2583677T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
JP2015509980A (ja) * | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法 |
US20140242029A1 (en) * | 2013-02-27 | 2014-08-28 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
WO2013143581A1 (en) | 2012-03-28 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in specific patient subgenotype sub-population |
WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4247479A (en) * | 1976-12-03 | 1981-01-27 | Hoechst Aktiengesellschaft | Process for the manufacture of aromatic amines from α, β-unsaturated cycloaliphatic ketoximes |
US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
PT858343E (pt) * | 1995-11-02 | 2004-07-30 | Schering Corp | Terapia por infusao continua de uma dose baixa de citoquina |
US6472373B1 (en) * | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
HU228218B1 (en) * | 1998-06-08 | 2013-02-28 | Hoffmann La Roche | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6824768B2 (en) * | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US6849254B1 (en) * | 1999-04-19 | 2005-02-01 | Schering Corporation | HCV combination therapy |
ATE367379T1 (de) * | 2000-08-09 | 2007-08-15 | Hoffmann La Roche | Quinolin-derivate als antientzündungsmittel |
EP2335700A1 (en) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7601709B2 (en) * | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
CA2522205A1 (en) * | 2003-04-10 | 2004-10-28 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
CN1771257A (zh) * | 2003-04-10 | 2006-05-10 | 贝林格尔·英格海姆国际有限公司 | 通过钌络合物催化的易位反应制备大环化合物的方法 |
ES2320771T3 (es) | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
JP4447603B2 (ja) * | 2003-05-21 | 2010-04-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビター化合物 |
WO2005016370A1 (en) * | 2003-08-13 | 2005-02-24 | Howard J. Smith & Associates Pty Ltd | Method of treating viral infections |
UY28525A1 (es) * | 2003-09-22 | 2005-04-29 | Boehringer Ingelheim Int | Péptidos macrociclicos activos contra en virus de la hepatitis c |
AR045870A1 (es) * | 2003-10-11 | 2005-11-16 | Vertex Pharma | Terapia de combinacion para la infeccion de virus de hepatitis c |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7410979B2 (en) * | 2003-11-19 | 2008-08-12 | Rigel Pharmaceuticals, Inc. | Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections |
NZ549079A (en) * | 2004-02-20 | 2010-08-27 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
AU2005224092A1 (en) * | 2004-03-15 | 2005-09-29 | Boehringer Ingelheim International, Gmbh | Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis C viral infections |
EA012389B1 (ru) | 2004-03-30 | 2009-10-30 | Интермун, Инк. | Макроциклические соединения в качестве ингибиторов вирусной репликации |
EP1753775B1 (en) * | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
DE102004033312A1 (de) * | 2004-07-08 | 2006-01-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren |
DE602005026294D1 (de) * | 2004-07-14 | 2011-03-24 | Novartis Ag | Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv) |
EP1794179A1 (en) * | 2004-09-17 | 2007-06-13 | Boehringer Ingelheim International Gmbh | Ring-closing metathesis process in supercritical fluid |
EP1794178A1 (en) * | 2004-09-17 | 2007-06-13 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic hcv protease inhibitors |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
PE20080197A1 (es) * | 2006-02-09 | 2008-04-11 | Schering Corp | Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s) |
WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
EP2162431B1 (en) | 2007-06-29 | 2017-06-07 | Gilead Sciences, Inc. | Antiviral compounds |
JP5465667B2 (ja) | 2007-06-29 | 2014-04-09 | ギリアード サイエンシーズ, インコーポレイテッド | 抗ウイルス化合物 |
WO2009014730A1 (en) | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
WO2009021121A2 (en) | 2007-08-08 | 2009-02-12 | Wyeth | Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto |
JP5574982B2 (ja) | 2008-02-04 | 2014-08-20 | イデニク プハルマセウティカルス,インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
EP2687526A1 (en) * | 2008-09-16 | 2014-01-22 | Boehringer Ingelheim International Gmbh | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor |
MX2011002602A (es) | 2008-09-17 | 2011-04-07 | Boehringer Ingelheim Int | Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina. |
TW201023858A (en) | 2008-09-18 | 2010-07-01 | Ortho Mcneil Janssen Pharm | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside |
JP5607736B2 (ja) * | 2009-07-07 | 2014-10-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ウイルスプロテアーゼ阻害剤のための医薬組成物 |
NZ598465A (en) * | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
US20120135949A1 (en) * | 2010-09-30 | 2012-05-31 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection |
-
2009
- 2009-09-14 MX MX2011002602A patent/MX2011002602A/es active IP Right Grant
- 2009-09-14 EA EA201100506A patent/EA019965B1/ru not_active IP Right Cessation
- 2009-09-14 CA CA2737376A patent/CA2737376A1/en not_active Abandoned
- 2009-09-14 CN CN2009801362929A patent/CN102159245B/zh not_active Expired - Fee Related
- 2009-09-14 KR KR1020117005679A patent/KR20110054003A/ko not_active Application Discontinuation
- 2009-09-14 AU AU2009293493A patent/AU2009293493B2/en not_active Ceased
- 2009-09-14 JP JP2011527889A patent/JP5539363B2/ja not_active Expired - Fee Related
- 2009-09-14 UA UAA201104531A patent/UA103496C2/uk unknown
- 2009-09-14 PE PE2011000635A patent/PE20110343A1/es not_active Application Discontinuation
- 2009-09-14 BR BRPI0918653A patent/BRPI0918653A2/pt not_active IP Right Cessation
- 2009-09-14 MY MYPI20111139 patent/MY152824A/en unknown
- 2009-09-14 EP EP09792492A patent/EP2337583A1/en not_active Withdrawn
- 2009-09-14 NZ NZ591030A patent/NZ591030A/xx not_active IP Right Cessation
- 2009-09-14 WO PCT/US2009/056771 patent/WO2010033443A1/en active Application Filing
- 2009-09-16 TW TW098131293A patent/TWI454263B/zh not_active IP Right Cessation
- 2009-09-16 UY UY0001032124A patent/UY32124A/es not_active Application Discontinuation
- 2009-09-16 AR ARP090103556A patent/AR073516A1/es unknown
- 2009-09-16 US US12/560,752 patent/US8399484B2/en active Active
-
2010
- 2010-12-20 ZA ZA2010/09151A patent/ZA201009151B/en unknown
- 2010-12-21 IL IL210152A patent/IL210152A0/en unknown
-
2011
- 2011-03-09 EC EC2011010877A patent/ECSP11010877A/es unknown
- 2011-03-14 MA MA33700A patent/MA32634B1/fr unknown
- 2011-03-16 CO CO11032826A patent/CO6351753A2/es not_active Application Discontinuation
- 2011-03-17 CL CL2011000571A patent/CL2011000571A1/es unknown
- 2011-10-20 HK HK11111257.2A patent/HK1156865A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ECSP11010877A (es) | 2011-04-29 |
IL210152A0 (en) | 2011-03-31 |
ZA201009151B (en) | 2011-09-28 |
CA2737376A1 (en) | 2010-03-25 |
CO6351753A2 (es) | 2011-12-20 |
TWI454263B (zh) | 2014-10-01 |
WO2010033443A1 (en) | 2010-03-25 |
EA201100506A1 (ru) | 2011-10-31 |
US8399484B2 (en) | 2013-03-19 |
AU2009293493B2 (en) | 2014-09-18 |
UA103496C2 (uk) | 2013-10-25 |
TW201016218A (en) | 2010-05-01 |
AR073516A1 (es) | 2010-11-10 |
KR20110054003A (ko) | 2011-05-24 |
JP5539363B2 (ja) | 2014-07-02 |
EA019965B1 (ru) | 2014-07-30 |
CN102159245A (zh) | 2011-08-17 |
MX2011002602A (es) | 2011-04-07 |
UY32124A (es) | 2010-04-30 |
HK1156865A1 (en) | 2012-06-22 |
CL2011000571A1 (es) | 2011-07-29 |
AU2009293493A1 (en) | 2010-03-25 |
US20100068182A1 (en) | 2010-03-18 |
PE20110343A1 (es) | 2011-06-25 |
MA32634B1 (fr) | 2011-09-01 |
MY152824A (en) | 2014-11-28 |
EP2337583A1 (en) | 2011-06-29 |
JP2012502999A (ja) | 2012-02-02 |
NZ591030A (en) | 2012-10-26 |
CN102159245B (zh) | 2013-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0918653A2 (pt) | combinação de inibidor de ns3 protese de hcv com interferon e ribavirina. | |
ATE501156T1 (de) | Cyclopropyl-annelierte indolobenzazepine als hcv- ns5b-inhibitoren | |
ATE493428T1 (de) | Hcv-nukleosidinhibitor | |
DK2373172T3 (da) | Hcv-ns5a-hæmmere | |
ECSP088157A (es) | Inhibidores de proteasa ns3 del vhc | |
BRPI0923184A2 (pt) | inibidores de hcv ns3 protease | |
IL194434A0 (en) | Hcv/hiv inhibitors and their uses | |
CR8540A (es) | Inhibidores de serina proteasa ns-3 del vhc | |
ZA201104911B (en) | Inhibitors of hcv ns5a | |
DK1924593T3 (da) | HCV NS3-proteaseinhibitorer | |
IL198401A0 (en) | Hcv ns3 protease inhibitors | |
EP2083844A4 (en) | HCV NS3 PROTEASE INHIBITORS | |
EP2079480A4 (en) | INHIBITORS OF HCV NS3 PROTEASE | |
EP2079479A4 (en) | INHIBITORS OF HCV NS3 PROTEASE | |
EP2076278A4 (en) | HCV NS3 PROTEASE INHIBITORS | |
EP2271345A4 (en) | HCV NS3 PROTEASE INHIBITORS | |
EP2125870A4 (en) | INHIBITORS OF NS3 PROTEASE OF HEPATITIS C | |
CR10923A (es) | Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion | |
BRPI0716483A2 (pt) | inibidores do vírus da hepatite c | |
BRPI0807087A2 (pt) | Inibidores de hcv macrocíclicos substituídos de pirimidina | |
IL194777A0 (en) | Hcv coreceptor and methods of use thereof | |
BRPI0919404A2 (pt) | combinações sinergísticas de um inibidor macrocíclico do hcv e de um nucleosídeo | |
DE602006003063D1 (de) | Tripeptid- und tetrapeptidsulfone | |
CR10430A (es) | Aminothiazoles and their uses | |
EP1881828A4 (en) | TREATMENT OF HEPATITIS C (HCV) USING SUB-THERAPEUTIC DOSES OF RIBAVIRIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |